- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06246084
INTENT Pilot Study - Enhancing Adherence Intentions to Endocrine Therapy
This research is being done to pilot an intervention which aims to improve participants' experiences on Endocrine Therapy.
The name of the intervention used in this research study is:
Endocrine Therapy Education Program (a brief, video-based intervention)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This research study is a randomized pilot study to determine whether a brief-video based intervention program can improve experiences of Endocrine Therapy (ET). Participants will be randomized into one of two groups: Group A: Endocrine Therapy Education Intervention vs. Group B Wait-list Control Group. Randomization means a participant is placed into a study group by chance.
The research study procedures include screening for eligibility, in-clinic visits, and survey questionnaires.
Participation in this research study is expected to last 3 months.
It is expected that about 60 people will take part in this research study.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Ann Partridge, MD, MPH
- Phone Number: 617-632-6800
- Email: ann_partridge@dfci.harvard.edu
Study Contact Backup
- Name: Ann Patridge, MD, MPH
- Phone Number: 617-632-6800
- Email: ann_partridge@dfci.harvard.edu
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02215
- Dana-Farber Cancer Institute
-
Contact:
- Ann Partridge, MD, MPH
- Phone Number: 617-632-6800
- Email: ann_partridge@dfci.harvard.edu
-
Principal Investigator:
- Ann Partridge, MD, MPH
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Biologically female
- About to begin or just started (within four weeks of starting) an oral form of ET (either tamoxifen or AI)
- 18 years of age or older
- English fluency for reading and writing.
- Computer literacy (ability to watch videos and fill out questionnaires online)
Exclusion Criteria:
- Adults unable to consent
- Individuals with metastatic cancer
- Individuals who are not yet adults (infants, children, teenagers)
- Pregnant women
- Prisoners
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Group A: Endocrine Therapy Education Intervention
Participants will complete:
|
Brief, video-based intervention program to improve endocrine therapy adherence and experiences and to provide detailed education to participants.
The intervention is distributed and assessed via the MyEmma platform, a HIPAA-compliant, online communications platform.
|
No Intervention: Group B: Wait-List Control Group
Participants will complete:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Engagement Rate of Intervention
Time Frame: 6 weeks
|
Adequate engagement of the intervention is defined as a click-to-open rate of 60% or over for the intervention group.
|
6 weeks
|
Intervention Satisfaction Questionnaire Mean Score Group A
Time Frame: At 6 weeks
|
Responses will be analyzed to determine a mean score for each item for the intervention group.
The Intervention Satisfaction Questionnaire includes 9 items rated on a 1 to 10 scale.
|
At 6 weeks
|
Intervention Satisfaction Questionnaire Mean Score Group B
Time Frame: At 14 weeks
|
Responses will be analyzed to determine a mean score for each item for the control group (following the release of the intervention educational videos).
The Intervention Satisfaction Questionnaire includes 9 items rated on a 1 to 10 scale.
|
At 14 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Ann Partridge, MD, MPH, Dana-Farber Cancer Institute
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 23-607
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonTerminatedBreast Cancer | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage III | Breast Cancer Stage IIB | Breast Cancer Stage IIA | Breast Cancer Stage IIIA | Breast Cancer Stage IIIB | Breast Cancer Stage IIIcUnited States
-
CelgeneCompletedBreast Cancer | Metastatic Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Breast Tumor | Cancer of the Breast | Triple-negative Metastatic Breast Cancer | Estrogen Receptor- Negative Breast Cancer | HER2- Negative Breast Cancer | Progesterone Receptor- Negative...United States, United Kingdom, Italy, Germany, Spain, Canada, Portugal, Australia, Austria, Greece, Brazil, France
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast...United States
-
University of Southern CaliforniaNational Cancer Institute (NCI)WithdrawnStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Susan G. Komen Breast Cancer FoundationCompletedStage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
Clinical Trials on Endocrine Therapy Education Program
-
Ottawa Hospital Research InstituteRecruiting
-
Katarzyna JóraszCompletedUrinary Incontinence,StressPoland
-
Ottawa Hospital Research InstituteCompleted
-
Atlanta VA Medical CenterUniversity of California, Los Angeles; University of Alabama at Birmingham; Emory... and other collaboratorsRecruitingInsomnia | NocturiaUnited States
-
Ondokuz Mayıs UniversityCompleted
-
The Third Xiangya Hospital of Central South UniversityNot yet recruitingQuality of Life | Lower Urinary Tract Symptoms | Advanced Prostate Cancer | Overall Survival | Progression of Prostate Cancer
-
Second Affiliated Hospital, School of Medicine,...RecruitingBreast Cancer | Elastography | Ultrasound | Radiomics | PathologyChina
-
Assistance Publique - Hôpitaux de ParisCompletedSubacute or Chronic Low Back PainFrance
-
ETOP IBCSG Partners FoundationAlliance for Clinical Trials in Oncology; Canadian Cancer Trials Group; Breast...Active, not recruitingEarly Breast CancerKorea, Republic of, United States, France, Canada, Spain, Lebanon, Belgium, Switzerland, Israel, Ireland, Japan, Italy, Denmark, Austria, Australia, Greece, Hungary, Netherlands, Norway, Portugal, Serbia, Slovenia
-
Haruhiko FukudaMinistry of Health, Labour and Welfare, JapanCompleted